What is the recommended duration and dosing schedule of oral vancomycin for an elderly patient with a third recurrence of Clostridioides difficile infection who cannot receive fidaxomicin?

Treatment of Third Recurrence of C. difficile with Oral Vancomycin

For this elderly patient with a third episode of C. difficile infection who cannot access fidaxomicin, use oral vancomycin in a tapered and pulsed regimen: 125 mg four times daily for 10-14 days, then 125 mg twice daily for 7 days, then 125 mg once daily for 7 days, then 125 mg every 2-3 days for 2-8 weeks. 1

Rationale for Tapered and Pulsed Regimen

The 2021 IDSA/SHEA guidelines explicitly recommend vancomycin in a tapered and pulsed regimen as an alternative treatment for second or subsequent CDI recurrences. 1 This approach is designed to:

• Suppress vegetative C. difficile during the initial high-dose phase while allowing gradual restoration of the intestinal microbiome 1
• Prevent germination of spores through intermittent pulse dosing that maintains periodic suppression 1
• Reduce recurrence risk compared to standard 10-day courses, which show recurrence rates of 20% or higher 2

Specific Dosing Schedule

The guideline-recommended tapered/pulsed vancomycin regimen example consists of: 1

1. Initial phase: 125 mg orally four times daily for 10-14 days
2. First taper: 125 mg twice daily for 7 days
3. Second taper: 125 mg once daily for 7 days
4. Pulse phase: 125 mg every 2-3 days for 2-8 weeks

The total duration ranges from approximately 5-11 weeks depending on the pulse phase length selected. 1

Important Clinical Considerations

Why Not Standard 10-Day Course?

A standard 10-day course of vancomycin 125 mg four times daily is listed as an option for second or subsequent recurrences 1, but the tapered and pulsed regimen is preferred because:

• Standard courses have high recurrence rates (20% in the original vancomycin trials) 2
• This patient has already failed two prior treatments, indicating high-risk status 1
• Elderly patients (>65 years) are at increased risk for recurrence, making extended therapy more appropriate 1

Alternative Regimen Option

Another guideline-endorsed alternative is vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days. 1 However, the tapered and pulsed vancomycin regimen is typically preferred when cost is a concern (since fidaxomicin is already unavailable due to coverage issues).

Monitoring for Nephrotoxicity

This elderly patient requires renal function monitoring during and after treatment. 3

• Oral vancomycin can achieve clinically significant serum concentrations in patients with inflammatory intestinal mucosa 3
• Nephrotoxicity risk is increased in patients >65 years of age 3
• Monitor serum creatinine during treatment, particularly given the extended duration of therapy 3

Evidence Supporting Extended Regimens

Research supports the efficacy of extended vancomycin regimens in recurrent CDI:

• Taper and pulse regimens show superior outcomes (58-100% success) compared to pulse-only regimens (26-81% success) 4
• Long-duration vancomycin (21-42 days) demonstrates lower recurrence rates (1.8%) compared to standard duration (11.7%) in high-risk populations 5
• Prolonged once-daily vancomycin at 125 mg for secondary prophylaxis shows only 1 relapse in 200 patient-months of follow-up 6

Additional Therapeutic Considerations

Bezlotoxumab

Consider adding bezlotoxumab 10 mg/kg IV once during vancomycin treatment if available and affordable. 1 This elderly patient has multiple risk factors for recurrence (age >65, multiple prior episodes), making bezlotoxumab particularly appropriate. 1 However, exercise caution if the patient has congestive heart failure. 1

Fecal Microbiota Transplantation

The IDSA/SHEA guidelines recommend that appropriate antibiotic treatments for at least 2 recurrences (i.e., 3 CDI episodes) should be tried prior to offering FMT. 1 After completing this third treatment course, if the patient experiences another recurrence, FMT should be strongly considered as the next step. 1

Common Pitfalls to Avoid

• Do not use IV vancomycin for C. difficile colitis—it is not effective and must be given orally 3
• Do not stop vancomycin prematurely if the patient requires concurrent systemic antibiotics for another infection; continue vancomycin until at least 5 days after the other antibiotics are completed 7
• Do not use the 125 mg dose assumption universally—while 125 mg four times daily is as effective as 500 mg four times daily for initial treatment 2, the tapered and pulsed regimen specifically uses 125 mg doses 1
• Do not forget to counsel the patient that the pulse phase involves taking medication every 2-3 days (not daily), which can be confusing 1